Allogene Therapeutics, Inc.

ALLO · Healthcare

$1.99

Capitalización: 685.8M USDRendimiento por dividendo: —
Advance¿Es buen momento para comprar Allogene Therapeutics, Inc.? Pregunta a Copenvest AIObtén una lectura Advance con IA sobre timing, riesgo y qué hacen los inversores rastreados.Preguntar a Copenvest AI

Cargando gráfico…

Noticias

Últimos titulares de esta acción

GlobeNewswire3 sept 2026, 12:00

Priothera Appoints Experienced Biotech Executive, Dr Nigel Clark, as Chief Business Officer to Lead Strategic Partnering for Mocravimod

MT Newswires2 sept 2026, 12:45

Allogene Therapeutics CFO Geoffrey Parker to Retire

BioPharma Dive2 sept 2026, 12:32

Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

GlobeNewswire2 sept 2026, 12:30

Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker

GlobeNewswire31 ago 2026, 12:30

Allogene Therapeutics Announces Participation in September Investor Conference